Clinical pharmacology of the novel marine-derived anticancer agent Ectainascidin 743 administered as a 1- and 3-h infusion in a phase I study

C. van Kesteren, C. Twelves, A. Bowman, K. Hoekman, L. López-Lázero, J.M. Jimeno, C. Guzman, R.A.A. Mathot, A. Simpson, J.B. Vermorken, J. Smyth, J.H.M. Schellens, M.J.X. Hillebrand, H. Rosing, J.H. Beijnen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)381-393
Number of pages12
JournalAnti-Cancer Drugs
Volume13
Publication statusPublished - 2002

Cite this